Form 4: Teladoc Director Converts RSUs to Common Stock

Teladoc Health Director Jason Eric Evans converted 1,016 restricted stock units into common stock on December 19, 2025, increasing his direct beneficial ownership.

Summary

• Jason Eric Evans, a Director at Teladoc Health, Inc. (TDOC), reported a transaction on December 19, 2025.
• He acquired 1,016 shares of common stock through the conversion of restricted stock units (RSUs).
• The RSUs convert to shares of TDOC common stock on a one-for-one basis at a price of $0.
• Following this transaction, Evans directly beneficially owns 9,145 shares of common stock.
• He also directly beneficially owns 3,050 derivative securities, specifically restricted stock units.
• The RSUs involved in this transaction were part of a grant of 12,195 RSUs on September 20, 2023, which vest one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects a routine vesting of equity compensation for a director, increasing their direct ownership and aligning their interests with shareholders. There are no negative implications from this specific transaction.

Positives

• Director Jason Eric Evans increased his direct beneficial ownership of Teladoc Health common stock by 1,016 shares, demonstrating continued alignment with shareholder interests.
• The transaction represents a routine vesting and conversion of previously granted restricted stock units, indicating a stable compensation structure for the director.

Negatives

• No negative aspects are directly indicated by this routine insider transaction.

Risks

• The filing itself does not introduce new specific risks beyond the general market risks associated with holding equity in Teladoc Health, Inc.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the ongoing vesting schedule of the director's restricted stock units.

Industry Context

This routine insider transaction reflects standard equity compensation practices for directors in publicly traded companies within the healthcare technology sector. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minor positive impact due to increased director ownership, which generally aligns management's interests with those of shareholders.
• Employees, Customers, Suppliers, Creditors: No direct or significant impact is indicated by this routine insider transaction.

Next Steps

• Remaining restricted stock units from the September 20, 2023 grant will continue to vest in eight substantially equal quarterly installments following the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the conversion of restricted stock units into common stock for a director. While it shows continued insider ownership, it does not provide new fundamental information about the company's financial health, operational performance, or strategic outlook that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this transaction alone does not alter the investment thesis.

Keywords

Teladoc Health, TDOC, Insider Transaction, Form 4, Restricted Stock Units, RSU Conversion, Director Ownership, Equity Compensation